| | A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metas . . . |
Ongoing |
24 May 2021 |
| | A Phase III Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A XR (a Fixed-dose Combination Tablet of Sitagliptin and Extended-rel . . . |
Completed |
01 Apr 2022 |
| | A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Alone or in Combination with Tremelimumab versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squa . . . |
Ongoing |
30 Oct 2020 |
| | A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patie . . . |
Completed |
18 May 2020 |
| | A Phase III Study to Assess the Immunogenicity and Safety of SK SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine adjuvanted with AS03 (GBP510) in Adults Aged 18 Years and Older . . . |
Ongoing |
28 Sep 2022 |
| | A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung C . . . |
Ongoing |
20 May 2020 |
| | A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in . . . |
Completed |
13 Feb 2020 |
| | A phase III, multicenter, observer blind, randomized, controlled study to evaluate immuneequivalence of multi-dose formulation against single-dose formulation of Vi-DT Typhoidconjugate vaccine and saf . . . |
Completed |
02 Aug 2021 |
| | A phase III, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult patients with stages AJCC/UIC . . . |
Ongoing |
20 May 2021 |
| | A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens ofMEDI3506 in Participants with Sy . . . |
Pending |
25 Oct 2022 |
| | A Phase III, Open-label, Multicentre, Randomised Trial to Establish Safety and Efficacy of an EGF Cancer Vaccine in Inoperable, Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients Eligible to . . . |
Terminated |
14 Apr 2020 |
| | A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB WITH LENVATINIB OR SORAFENIB VERSUS LENVATINIB OR SORAFENIB ALONE IN HEPATOCELLULAR CARCINOMA PREVIOUSLY TREATED WITH ATEZOLIZUMAB AND BEVACIZ . . . |
Ongoing |
30 Nov -0001 |
| | A Phase III, Open-label, Randomized Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutatio . . . |
Ongoing |
12 Jan 2021 |
| | A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicenter, Study of Durvalumab as Consolidation Therapy in Patients with Locally Advanced, Unresectable, Non-Small Cell Lung Cancer (Stage . . . |
Ongoing |
11 Mar 2021 |
| | A Phase III, Randomized, Double-blind Study to Assess the Efficacy and Safety of Lazertinib versus Gefitinib as the First-line Treatment in Patients with Epidermal Growth Factor Receptor Sensitizing M . . . |
Ongoing |
04 May 2023 |
| | A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and following Chemoradiotherapy Compared to Chemoradiotherapy A . . . |
Ongoing |
29 Jan 2021 |
| | A phase III, randomized, observer-blind, active-controlled, parallel-group, multi-center study to evaluate immunogenicity and safety of a preventive COVID-19 vaccine EuCorVac-19 in healthy adults aged . . . |
Ongoing |
17 Mar 2023 |
| | A Phase III, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus’ Cell-Based Quadrivalent SubunitInfluenza Virus Vaccine (QIVc) Compared to a . . . |
Ongoing |
06 Feb 2023 |
| | A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab a . . . |
Ongoing |
18 May 2020 |
| | A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine + Cisplatin for Neoadjuvant Treatment Followed by Dur . . . |
Ongoing |
04 Apr 2022 |
| | A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician’s Choice of Adjuvant Endocrine Monotherapy in Patients with . . . |
Ongoing |
17 Feb 2022 |
| | A Phase Ⅲ Clinical Trial of Influenza Virus Vector COVID19 Vaccine for Intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1 . . . |
Ongoing |
10 Jan 2023 |
| | A Phase Ⅲ, randomized, double-blind and controlled clinical trial to evaluate the Immunogenicity and safety of Influenza vaccine (Split virion), Inactivated, Quadrivalent developed by Sinovac Biotec . . . |
Ongoing |
23 Feb 2023 |
| | A Prospective, Multi-Centre Study (B-Sure) to Evaluate Long-Term Durability of Sustained Virologic Response in Chronic Hepatitis B Participants With and Without Nucleos(t)ide Therapy Who Have Received . . . |
Pending |
30 Nov -0001 |
| | A prospective, multi-national, multi-center, open-label, randomized, active-controlled, parallel-group, operationally seamless Phase 2/3 clinical study to evaluate the immunogenicity, safety and lot-t . . . |
Ongoing |
06 Feb 2023 |